低分子肝素钙治疗肺心病并呼吸衰竭的效果研究
2016-01-20官宇男
官宇男
低分子肝素钙治疗肺心病并呼吸衰竭的效果研究
官宇男
【摘要】目的对低分子肝素治疗肺心病并呼吸衰竭的临床效果进行研究。方法 选取2013年7月~2015年7月我院接受治疗的肺心病并呼吸衰竭患者97例,将患者随机分为对照组(46例)和治疗组(51例)进行对照组研究,观察常规治疗和低分子肝素治疗的效果并进行比较。结果 治疗组患者的显效率、好转率以及治疗总有效率分别为60.8%、31.4%和92.2%,均高于对照组患者的47.8%、23.9%和28.3%,差异具有统计学意义(P<0.05)。结论 对肺心病并呼吸衰竭采用低分子肝素治疗具有疗效,能使治疗效果得到显著提高,使患者的缺氧情况、肺循环以及呼吸功能得到改善。
【关键词】低分子肝素;肺心病;呼吸衰竭
作者单位: 138000 吉林省松原市中心医院
Low Molecular Heparin in Treatment of Pulmonary and Respiratory Failure After Heart Disease Research
GUAN Yunan, Songyuan Central Hospital, Songyuan 138000, China
[Abstract]Objective To LMWH pulmonary heart disease and respiratory failure were studied clinical results. Methods In July 2013 to July 2015 in our hospital for treatment of respiratory failure in patients with pulmonary heart disease and 97 cases, the patients were randomly divided into control group(46 cases)and treatment group(51 patients)in the control group study, the observed effect of conventional treatment and low molecular weight heparin and compared. Results The treatment group were significantly efficiency improvement rate and the total effective rate was respectively 60.8%, 31.4% and 92.2%, significantly higher than 47.8% of patients, 23.9% and 28.3%, significantly different statistically significance(P<0.05). Conclusion Pulmonary Heart Disease and Respiratory Failure using low molecular weight heparin having a significant effect, the therapeutic effect can be significantly improved and the hypoxia, pulmonary circulation and respiratory function of patients improved.
[Key words]Low molecular weight heparin, Pulmonary heart disease, Respiratory failure
肺源性心脏病(肺心病)是临床上一种较为常见并且多发的心脏疾病,可以分为慢性和急性两种类型,随着患者病情的发展,患者会出现呼吸衰竭等严重的并发症,甚至会导致死亡[1]。目前临床上对于肺心病并呼吸衰竭的药物治疗方案较多,本院对2013 年7月~2015年7月期间在我院接受治疗的肺心病并呼吸衰竭患者,在常规治疗的基础上采用低分子肝素辅助治疗,疗效确切,现将研究结果报告如下。
1 资料和方法
1.1一般资料
选取于2013年7月~2015年7月期间在我院接受治疗的肺心病并呼吸衰竭患者97例,所有患者均符合该病的相关临床诊断标准。将患者随机分为对照组46例患者和治疗组51例患者,对照组患者中有21例患者为女性,25例患者为男性;……
